Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC-A12 in Asymptomatic, Chemotherapy-Naïve Metastatic Androgen-Independent Prostate Cancer
NCT00520481Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2007
- Primary completion
- Jan 2012
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cixutumumab in prostate cancer (PCa), sponsored by Eli Lilly and Company. Started Aug 2007; status: completed.
02
Drugs
cixutumumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00520481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00520481.